Relmada Therapeutics (RLMD) EBT Margin (2012 - 2013)
Relmada Therapeutics' (RLMD) quarterly EBT Margin came in at 776.97% in Q4 2013, down 34286.0% year-on-year from N/an in Q4 2012, and up 74.72% on a QoQ basis from 3073.34% in Q2 2013.
Relmada Therapeutics (RLMD) EBT Margin (2012 - 2013) Analysis & Trends
Relmada Therapeutics (RLMD) has 2 years of EBT Margin data on file, last reported at 776.97% in Q4 2013.
- On a quarterly basis, EBT Margin fell 34286.0% year-over-year to 776.97% in Q4 2013; TTM through Nov 2013 was 652.71%, a N/A change from a year earlier, with the FY2013 full-year figure at 737.24%, down 64992.0% from the prior year.
- EBT Margin for Q4 2013 stood at 776.97%, up from 3073.34% in the prior quarter.
- Over the last five years, EBT Margin for RLMD reached as high as 207.54% in Q1 2013 and fell as low as 3073.34% in Q2 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Relmada Therapeutics | 205.29 Mn | 205.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Nov 30, 2013 | -776.97% |
| May 31, 2013 | -3,073.34% |
| Feb 28, 2013 | -207.54% |
| Nov 30, 2012 | -434.11% |
| Aug 31, 2012 | -231.75% |
| May 31, 2012 | -1,267.50% |